Quantifying comorbidity in a disease-specific cohort: adaptation of the total illness burden index to prostate cancer.
about
Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysisDo self-report and medical record comorbidity data predict longitudinal functional capacity and quality of life health outcomes similarly?Development of prostate cancer research database with the clinical data warehouse technology for direct linkage with electronic medical record system.Constructs of burden of illness in older patients with breast cancer: a comparison of measurement methodsMental health symptoms and patient-reported diabetes symptom burden: implications for medication regimen changes.Patient complexity and risk factor control among multimorbid patients with type 2 diabetes: results from the R2D2C2 study.Severity of cardiovascular disease and health-related quality of life in men with prostate cancer: a longitudinal analysis from CaPSUREUsing a population-based observational cohort study to address difficult comparative effectiveness research questions: the CEASAR study.Tissue vaccines for cancer.The relative merits of population-based and targeted prevention strategiesConsideration of comorbidity in risk stratification prior to prostate biopsy.The Influence of Psychosocial Constructs on the Adherence to Active Surveillance for Localized Prostate Cancer in a Prospective, Population-based Cohort.The implications of ageing and life expectancy in prostate cancer treatment.Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years.Racial Variation in Patient-Reported Outcomes Following Treatment for Localized Prostate Cancer: Results from the CEASAR Study.Assessing the impact of comorbid illnesses on death within 10 years in prostate cancer treatment candidates.Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.Quality of life following breast-conserving therapy or mastectomy: results of a 5-year prospective study.Authorship of articles in CMAJ: who goes first?Who can respond to treatment? Identifying patient characteristics related to heterogeneity of treatment effects.From bad to worse: comorbidity severity and quality of life after treatment for early-stage prostate cancer.Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPET.
P2860
Q28196553-3AC7F0F4-67D3-4A45-B058-11EBB24CCD8BQ30577458-E552D1FB-6798-44EF-AA95-0DD4335895D5Q30693970-2F64E8C8-BF9E-45F9-ABB0-3085C3EDAA9AQ33774297-D81F59EA-26CD-4DDF-BB2A-7BD0FFF25A4AQ35975189-C8C0C884-6E89-4684-895C-909431B05E21Q36553220-8B74AAAE-0717-41D5-9A50-90A98A6C6107Q36800371-513C9507-F17B-43A3-94F5-7966E5844F25Q37035993-311A4D5D-E6CD-400C-AB5A-49D9D4CE14DAQ37123446-C11A06CC-F338-4265-8AB8-5AEFF77104F3Q37212186-220E2332-BAC2-4781-8976-5BE39256F139Q37415134-7E1A9FDF-E8AF-4003-80E0-D0AA95ADD796Q38758510-3CEE8329-20B1-49E4-8EB1-132FFC99EC7CQ38784043-AB232B9E-2957-44E9-A57B-8AF27A438F94Q38890085-26F2B281-6667-42B7-96B4-2E515B1E7DA1Q39212848-B21E6E98-F5FE-45A6-858C-1B0BCE9CF239Q39715470-9F34D11B-2979-4455-AE52-7560896D73ABQ39727032-F66B53D1-FFAD-46E5-ACAD-CCEE9537D2EDQ40512796-E8B9B5C0-27EF-4482-91ED-7C60D24AA480Q42720921-309026D1-AC78-427F-A001-FB15BDD15697Q43062167-00609C6C-8A6A-4803-8FEC-E10406DEAD2FQ44770492-BD8AB394-1F0C-46A8-BD59-380BEC522C9EQ50124344-DD635678-4270-4080-8961-C514418EDF81
P2860
Quantifying comorbidity in a disease-specific cohort: adaptation of the total illness burden index to prostate cancer.
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Quantifying comorbidity in a d ...... rden index to prostate cancer.
@ast
Quantifying comorbidity in a d ...... rden index to prostate cancer.
@en
type
label
Quantifying comorbidity in a d ...... rden index to prostate cancer.
@ast
Quantifying comorbidity in a d ...... rden index to prostate cancer.
@en
prefLabel
Quantifying comorbidity in a d ...... rden index to prostate cancer.
@ast
Quantifying comorbidity in a d ...... rden index to prostate cancer.
@en
P2093
P1433
P1476
Quantifying comorbidity in a d ...... urden index to prostate cancer
@en
P2093
D P Lubeck
J M Henning
S C Flanders
S H Kaplan
P304
P356
10.1016/S0090-4295(99)00203-4
P407
P577
1999-09-01T00:00:00Z